ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone734-335-0468
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10,000.00
Profitability
Miscellaneous
Employees11
Next Earnings Date3/9/2020 (Estimated)
OptionableNot Optionable
ENDRA Life Sciences (NASDAQ:NDRA) Frequently Asked Questions
What is ENDRA Life Sciences' stock symbol?
ENDRA Life Sciences trades on the NASDAQ under the ticker symbol "NDRA."
How were ENDRA Life Sciences' earnings last quarter?
ENDRA Life Sciences Inc (NASDAQ:NDRA) released its quarterly earnings data on Wednesday, November, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.27. View ENDRA Life Sciences' Earnings History.
When is ENDRA Life Sciences' next earnings date?
What price target have analysts set for NDRA?
3 Wall Street analysts have issued 1 year target prices for ENDRA Life Sciences' stock. Their forecasts range from $6.00 to $6.00. On average, they expect ENDRA Life Sciences' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 471.4% from the stock's current price. View Analyst Price Targets for ENDRA Life Sciences.
What is the consensus analysts' recommendation for ENDRA Life Sciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ENDRA Life Sciences.
Has ENDRA Life Sciences been receiving favorable news coverage?
Media stories about NDRA stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ENDRA Life Sciences earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for ENDRA Life Sciences.
Who are some of ENDRA Life Sciences' key competitors?
Some companies that are related to ENDRA Life Sciences include Precision Optics (PEYE), Helius Medical Technologies (HSDT), Digirad (DRAD), Non-Invasive Monitoring Systems (NIMU), Vaso (VASO), Nexeon Medsystems (NXNN), CHF Solutions (CHFS), ReShape Lifesciences (RSLSD), Viveve Medical (VIVE), Escalon Medical (ESMC), Trimedyne (TMED), Guided Therapeutics (GTHP), Magna-Lab (MAGAA), Newcardio (NWCI) and Echo Therapeutics (ECTE).
What other stocks do shareholders of ENDRA Life Sciences own?
Who are ENDRA Life Sciences' key executives?
ENDRA Life Sciences' management team includes the folowing people:
- Mr. Francois Michelon, Chairman & CEO (Age 53)
- Mr. David R. Wells, CFO & Sec. (Age 57)
- Mr. Michael Thornton, Chief Technology Officer (Age 51)
- Dr. Jonathan Behr Ph.D., Co-Founder
- Mr. Steve Freeman, HR Leader
When did ENDRA Life Sciences IPO?
(NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO.
Who are ENDRA Life Sciences' major shareholders?
ENDRA Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.38%). Company insiders that own ENDRA Life Sciences stock include David R Wells, Longboard Capital Advisors, Ll, Michael Harsh and Michael Milos Thornton. View Institutional Ownership Trends for ENDRA Life Sciences.
Which major investors are buying ENDRA Life Sciences stock?
NDRA stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought ENDRA Life Sciences stock in the last two years include David R Wells, Michael Harsh and Michael Milos Thornton. View Insider Buying and Selling for ENDRA Life Sciences.
How do I buy shares of ENDRA Life Sciences?
Shares of NDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ENDRA Life Sciences' stock price today?
One share of NDRA stock can currently be purchased for approximately $1.05.
How big of a company is ENDRA Life Sciences?
ENDRA Life Sciences has a market capitalization of $7.89 million and generates $10,000.00 in revenue each year. The company earns $-9,800,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. ENDRA Life Sciences employs 11 workers across the globe.View Additional Information About ENDRA Life Sciences.
What is ENDRA Life Sciences' official website?
How can I contact ENDRA Life Sciences?
ENDRA Life Sciences' mailing address is 3600 GREEN COURT SUITE 350, ANN ARBOR MI, 48105. The company can be reached via phone at 734-335-0468 or via email at [email protected]
MarketBeat Community Rating for ENDRA Life Sciences (NASDAQ NDRA)
MarketBeat's community ratings are surveys of what our community members think about ENDRA Life Sciences and other stocks. Vote "Outperform" if you believe NDRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NDRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
